ARHS
Arhaus, Inc.
ARHS's outlook is improving, though it still trails on the overall score.
NKE
NIKE, Inc.
NKE has the edge over ARHS overall, supported by stronger valuation and lower modeled downside.
ARHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Strong |
ARHS's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
NKE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
NKE's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
ARHS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $4.81 | -64% |
| Fair | 18x | $8.20 | -39% |
| Expensive | 22x | $10.24 | -24% |
| Forward | 24x | $13.52 | — |
| Current | 29x | $13.52 | — |
Historical ranges are pointers, not guarantees.
ARHS's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 24x next year's earnings.
NKE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $37.76 | — |
| Cheap | 23x | $47.70 | +26% |
| Forward | 30x | $37.76 | — |
| Fair | 33x | $68.16 | +80% |
| Expensive | 47x | $97.86 | +159% |
Historical ranges are pointers, not guarantees.
NKE has the edge over ARHS in the historical PE scenario, which offers more potential upside but is not a forecast.
ARHS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
ARHS has the edge over NKE on the outlook, with more favorable valuation and earnings expectations.
NKE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Decline | |
| Improving | |
| Moderate | |
| Low |
Analysts expect NKE's profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
ARHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.56 | +22% |
| Q3 2026 | $0.46 | -12% |
| Q2 2026 | $0.50 | 0% |
| Q1 2026 | $0.47 | +15% |
| Q4 2025 | $0.48 | -2% |
| Q3 2025 | $0.52 | -7.1% |
| Q2 2025 | $0.50 | -21% |
| Q1 2025 | $0.41 | -46% |
| Q4 2024 | $0.49 | -45% |
ARHS has the edge over NKE on earnings, with stronger typical year-over-year growth.
NKE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.27 | -39% |
| Q3 2026 | $2.09 | +7.2% |
| Q2 2026 | $2.10 | -2.8% |
| Q1 2026 | $1.51 | -50% |
| Q4 2025 | $1.70 | -48% |
| Q3 2025 | $1.95 | -44% |
| Q2 2025 | $2.16 | -42% |
| Q1 2025 | $3.01 | -11% |
| Q4 2024 | $3.24 | -5.3% |
NKE's earnings per share have fallen from their peak: $2.09 over the past year, against $3.82 in late 2021.
ARHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $368.1M | +6.8% |
| Q2 2026 | $384.9M | +7.4% |
| Q1 2026 | $314.3M | +0.9% |
| Q4 2025 | $364.8M | +5.1% |
| Q3 2025 | $344.6M | +8% |
| Q2 2025 | $358.4M | +16% |
| Q1 2025 | $311.4M | +5.5% |
| Q4 2024 | $347M | +0.9% |
ARHS has the edge over NKE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.7% | -2 points |
| Q2 2026 | 14% | +1 points |
| Q1 2026 | 0.7% | -1.1 points |
| Q4 2025 | 5.5% | -2.7 points |
| Q3 2025 | 4.8% | +1.4 points |
| Q2 2025 | 13% | +3.6 points |
| Q1 2025 | 1.7% | -4.5 points |
| Q4 2024 | 8.2% | -3.7 points |
ARHS's operating margin was 2.7% last quarter, down 2 points from the same quarter a year ago.
NKE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.2B | -4.3% |
| Q2 2026 | $11B | -1.1% |
| Q1 2026 | $11.3B | +0.1% |
| Q4 2025 | $12.4B | +0.6% |
| Q3 2025 | $11.7B | +1.1% |
| Q2 2025 | $11.1B | -12% |
| Q1 2025 | $11.3B | -9.3% |
| Q4 2024 | $12.4B | -7.7% |
NKE's revenue fell from its 2023 peak and has held roughly level since: $11.2B last quarter, down 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.2% | +0.3 points |
| Q2 2026 | 12% | +9.2 points |
| Q1 2026 | 5.8% | -1.7 points |
| Q4 2025 | 8% | -3.4 points |
| Q3 2025 | 7.9% | -3.4 points |
| Q2 2025 | 2.9% | -11 points |
| Q1 2025 | 7.5% | -3.8 points |
| Q4 2024 | 11% | -2.9 points |
NKE has the edge over ARHS on profitability, with a higher operating margin.
ARHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $91.9M | +228% |
| Q2 2026 | $48.3M | +131% |
| Q1 2026 | -$26.6M | -241% |
| Q4 2025 | -$8.8M | -168% |
| Q3 2025 | $28M | +509% |
| Q2 2025 | $20.9M | +86% |
| Q1 2025 | $18.9M | +73% |
| Q4 2024 | $13M | +$26.8M |
ARHS has the edge over NKE on cash flow, with more consistent year-over-year improvement.
NKE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$64M | -527% |
| Q2 2026 | $1.5B | +313% |
| Q1 2026 | $284M | -83% |
| Q4 2025 | $386M | -58% |
| Q3 2025 | $15M | -95% |
| Q2 2025 | $363M | -85% |
| Q1 2025 | $1.7B | -11% |
| Q4 2024 | $920M | -65% |
NKE usually generates cash, though not every quarter: the latest was −$64M, but it generated $2.1B over the past year.
ARHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +467K shares |
| 1 year | +0.4% | +598K shares |
| 3 years | +1.5% | +2.1M shares |
| 5 years | +27% | +30.2M shares |
| Available history | +401% | +114M shares |
ARHS has 142M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $50,000 |
| Q1 2020 | $50,000 |
NKE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.2M shares |
| 1 year | +0.4% | +5.2M shares |
| 3 years | -3.8% | -59.1M shares |
| 5 years | -8.4% | -135M shares |
| Available history | -6.9% | -110M shares |
NKE has the edge over ARHS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $20M |
| Q3 2025 | $126M |
| Q2 2025 | $199M |
| Q1 2025 | $506M |
| Q4 2024 | $1.1B |
NKE has spent almost nothing on buybacks in the past year.
ARHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.3x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.7x | Net Cash |
| Q1 2025 | -1.9x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
ARHS has the edge over NKE on leverage, with a lower net debt burden relative to earnings.
NKE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.1x | Very low |
| Q2 2024 | -0.1x | Net Cash |
| Q1 2024 | -0.0x | Very low |
| Q4 2023 | 0.1x | Very low |
NKE's net debt is less than a year of its operating earnings (EBITDA).
ARHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.0 | Neutral |
| Stochastic | 90.6 | Overbought |
ARHS's weekly RSI is 69 (neutral) and its Stochastic is 91 (overbought).
NKE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 57.5 | Neutral |
NKE's weekly RSI is 40 (neutral) and its Stochastic is 58 (neutral).
ARHS PE vs Consumer Cyclical Sector
| Metric | ARHS | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 18x | 63% above |
| PE % | 96 | 56 | 40 pts above |
ARHS is trading at 29x earnings, a 63% premium to the Consumer Cyclical sector's median of 18x.
NKE PE vs Consumer Cyclical Sector
| Metric | NKE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 18x | 0.3% above |
| PE % | 2 | 47 | 45 pts below |
NKE has the edge over ARHS on valuation relative to its sector.
ARHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.4 | 18% above |
| 20 week MA | $9.67 | 40% above |
| 50 week MA | $8.97 | 51% above |
| 100 week MA | $9.41 | 44% above |
| 200 week MA | $10.5 | 29% above |
ARHS has the edge over NKE on trend strength, trading above more of its moving averages.
NKE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.7 | 2.8% above |
| 20 week MA | $39.2 | 3.6% below |
| 50 week MA | $48.0 | 21% below |
| 100 week MA | $58.4 | 35% below |
| 200 week MA | $79.2 | 52% below |
NKE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 52% below its 200-week average.
ARHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12.2 | $10.4 | -15% |
| 2022 | $10.4 | $9.24 | -11% |
| 2023 | $9.24 | $11.9 | +28% |
| 2024 | $11.9 | $9.26 | -22% |
| 2025 | $9.26 | $11.7 | +27% |
| 2026 YTD | $11.7 | $13.5 | +15% |
ARHS has the edge over NKE on returns for 2026, with the stronger performance.
NKE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.6 | $141.6 | +39% |
| 2021 | $141.6 | $165.7 | +17% |
| 2022 | $165.7 | $116.3 | -30% |
| 2023 | $116.3 | $108.6 | -6.6% |
| 2024 | $108.6 | $76.4 | -30% |
| 2025 | $76.4 | $60.9 | -20% |
| 2026 YTD | $60.9 | $37.8 | -38% |
NKE has finished four years in a row lower, and it's down 38% so far in 2026.